- Home
- STRO
STRO
Sutro Biopharma Inc.
as 06-20-2025 3:41pm EST
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 77.7M | IPO Year: | 2018 |
| Target Price: | $3.97 | AVG Volume (30 days): | 833.9K |
| Analyst Decision: | Hold | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.52 - $5.17 | Next Earning Date: | 08-12-2025 |
| Revenue: | $66,434,000 | Revenue Growth: | -56.88% |
| Revenue Growth (this year): | -6.99% | Revenue Growth (next year): | -23.65% |
Latest Sutro Biopharma Inc. News
STRO Breaking Stock News: Dive into STRO Ticker-Specific Updates for Smart Investing
MT Newswires
6 days ago
Piper Sandler Upgrades Sutro Biopharma to Overweight From Neutral, $2 Price Target
GlobeNewswire
20 days ago
Sutro Biopharma Appoints Greg Chow as Chief Financial Officer
Simply Wall St.
a month ago
Sutro Biopharma First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Zacks
a month ago
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
a month ago
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
2 months ago
Sutro Biopharma to Participate in Upcoming Investor Conferences
GlobeNewswire
2 months ago
Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025
TipRanks
3 months ago
Reddit initiated, Netflix upgraded: Wall Street’s top analyst calls
Compare STRO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STRO Sutro Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.